Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06958874
Recruiting Not applicable

Adjunctive Effect of Erythritol on Pocket Closure Rates

NCT06958874 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2024-11-08
Last updated
2025-05-06

Condition(s) studied

PeriodontitisPocket, PeriodontalPocket, Gingival

Investigational drug(s) / intervention(s)

Non-surgical periodontal therapy + sub-gingival air polishingNon-surgical periodontal therapy alone

Non-surgical periodontal therapy + sub-gingival air polishing: Participants receive a single session of non-surgical periodontal therapy (NSPT) using ultrasonic and manual instruments, combined with sub-gingival air polishing using erythritol powder. The treatment is applied to periodontal pockets with probing depth ≥ 4 mm in non-adjacent teeth.

Non-surgical periodontal therapy alone: Participants receive a single session of non-surgical periodontal therapy (NSPT) using ultrasonic and manual instruments.

Study summary

This clinical trial is studying whether using erythritol powder during non-surgical periodontal treatment (deep cleaning) helps improve gum health in people with severe periodontitis. Participants with deep gum pockets (4 mm or more) receive standard treatment alone or standard treatment plus cleaning with erythritol powder. The goal is to evaluate if adding erythritol improves outcomes such as healing of gum pockets, bleeding, plaque levels, and gum attachment compared to standard treatment alone.

Eligibility

Sex
ALL
Min age
35 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Adults aged 18 years or older Diagnosed with stage 3 or 4 periodontitis according to the 2017 classification Presence of at least 12 natural teeth Presence of periodontal pockets with probing depth ≥ 4 mm in non-adjacent teeth Good general health or stable systemic conditions (e.g., controlled diabetes) Exclusion Criteria: Use of antibiotics or anti-inflammatory drugs within 3 months prior to treatment Periodontal treatment in the previous 6 months Pregnancy or breastfeeding Current smokers of more than 10 cigarettes per day Allergies or intolerance to erythritol or any materials used in the treatment Systemic diseases or conditions that could influence periodontal healing (e.g., uncontrolled diabetes, immunodeficiency) Use of medications known to affect periodontal tissues (e.g., phenytoin, cyclosporine, calcium channel blockers)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of L'Aquila L’Aquila Italy Recruiting

More University of L'Aquila trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06958874 on ClinicalTrials.gov ↗ ← All trials in Italy